

# Brian A Keller

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9504295/publications.pdf>

Version: 2024-02-01

10  
papers

194  
citations

1306789

7  
h-index

1473754

9  
g-index

10  
all docs

10  
docs citations

10  
times ranked

413  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Dimethyl fumarate potentiates oncolytic virotherapy through NF- $\kappa$ B inhibition. <i>Science Translational Medicine</i> , 2018, 10, .   | 5.8 | 44        |
| 2  | Oncolytic viruses as immunotherapeutics on the rise. <i>Journal of Molecular Medicine</i> , 2016, 94, 979-991.   | 1.7 | 43        |
| 3  | Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition. <i>Molecular Therapy</i> , 2019, 27, 1139-1152.  | 3.7 | 41        |
| 4  | Oncolytic Viruses: The Best is Yet to Come. <i>Current Cancer Drug Targets</i> , 2018, 18, 109-123.  | 0.8 | 19        |
| 5  | Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 179-187.   | 2.0 | 16        |
| 6  | Virally programmed extracellular vesicles sensitize cancer cells to oncolytic virus and small molecule therapy. <i>Nature Communications</i> , 2022, 13, 1898.   | 5.8 | 16        |
| 7  | Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16027.                 | 2.0 | 11        |
| 8  | Personalized oncology and BRAF <sup>K601N</sup> melanoma: model development, drug discovery, and clinical correlation. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1365-1378. | 1.2 | 2         |
| 9  | Performance report for a 10-year-old MD/PhD Program: A survey of trainees at the University of Ottawa. <i>Clinical and Investigative Medicine</i> , 2020, 43, E1-13.                                   | 0.3 | 2         |
| 10 | Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses. <i>Methods in Molecular Biology</i> , 2020, 2058, 271-284.                               | 0.4 | 0         |